RxDoctor Payments Data

Rehan Naseemuddin, MD

Gastroenterology · Jacksonville, FLNPI 1083024715

Payments from drug & device makers

$41,205in general payments, 2019–2025

Across 275 payments — averaging $149.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$22K
  • Phathom Pharmaceuticals, Inc.$15K
  • Johnson & Johnson$621
  • Madrigal Pharmaceuticals$365
  • Boston Scientific$340
  • Sanofi$330
  • plus $2K from 24 others

What the payments were for

  • Speaking & faculty fees$33,73382%
  • Travel & lodging$8252%
  • Food & beverage$6,54816%
  • Education$1000%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,205 in reported general payments places this provider in the 85th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$113,252
Medicare patients
394
Services billed
948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib18$171,747
LinzessLinaclotide91$70,907
XifaxanRifaximin17$55,731
RezdiffraResmetirom12$49,810
CreonLipase/Protease/Amylase11$28,577
VoqueznaVonoprazan Fumarate12$13,444
Omeprazole90$1,667
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl94$1,458
Pantoprazole Sodium91$1,242
Dicyclomine Hcl43$759
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl12$165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess, Creon$22,372$271,231120 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$262$55,73117 claims
Madrigal PharmaceuticalsRezdiffra$365$49,81012 claims
Phathom Pharmaceuticals, Inc.Voquezna$15,154$13,44412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →